These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Long-term treatment of rectovaginal fistulas in Crohn's disease: response to infliximab in the ACCENT II Study. Sands BE; Blank MA; Patel K; van Deventer SJ; Clin Gastroenterol Hepatol; 2004 Oct; 2(10):912-20. PubMed ID: 15476155 [TBL] [Abstract][Full Text] [Related]
4. Maintenance infliximab does not result in increased abscess development in fistulizing Crohn's disease: results from the ACCENT II study. Sands BE; Blank MA; Diamond RH; Barrett JP; Van Deventer SJ Aliment Pharmacol Ther; 2006 Apr; 23(8):1127-36. PubMed ID: 16611273 [TBL] [Abstract][Full Text] [Related]
5. Retreatment and maintenance therapy with infliximab in fistulizing Crohn's disease. Rodrigo L; Pérez-Pariente JM; Fuentes D; Cadahia V; García-Carbonero A; Niño P; de Francisco R; Tojo R; Moreno M; González-Ballina E Rev Esp Enferm Dig; 2004 Aug; 96(8):548-54; 554-8. PubMed ID: 15449986 [TBL] [Abstract][Full Text] [Related]
6. Combined approach with infliximab, surgery, and methotrexate in severe fistulizing anoperineal Crohn's disease: results from a prospective study. Roumeguère P; Bouchard D; Pigot F; Castinel A; Juguet F; Gaye D; Capdepont M; Zerbib F; Laharie D Inflamm Bowel Dis; 2011 Jan; 17(1):69-76. PubMed ID: 20623697 [TBL] [Abstract][Full Text] [Related]
7. Combining infliximab and methotrexate in fistulizing Crohn's disease resistant or intolerant to azathioprine. Schröder O; Blumenstein I; Schulte-Bockholt A; Stein J Aliment Pharmacol Ther; 2004 Feb; 19(3):295-301. PubMed ID: 14984376 [TBL] [Abstract][Full Text] [Related]
8. Infliximab in treatment of Crohn's disease: the Milan experience. Ardizzone S; Colombo E; Maconi G; Bollani S; Manzionna G; Petrone MC; Bianchi Porro G Dig Liver Dis; 2002 Jun; 34(6):411-8. PubMed ID: 12132788 [TBL] [Abstract][Full Text] [Related]
9. Infliximab improves quality of life in the short-term in patients with fistulizing Crohn's disease in clinical practice. Cadahia V; García-Carbonero A; Vivas S; Fuentes D; Niño P; Rebollo P; Rodrigo L Rev Esp Enferm Dig; 2004 Jun; 96(6):369-74; 374-8. PubMed ID: 15230666 [TBL] [Abstract][Full Text] [Related]
10. Predictors of response to infliximab in patients with fistulizing Crohn's disease. Luna-Chadid M; Pérez Calle JL; Mendoza JL; Vera MI; Bermejo AF; Sánchez F; López San Román A; Froilán C; González-Lara V; García-Paredes J; Fernández-Blanco I; Abreu L; Casis B; Solís Herruzo JA; Gisbert JP; Maté Jiménez J Rev Esp Enferm Dig; 2004 Jun; 96(6):379-81; 382-4. PubMed ID: 15230667 [TBL] [Abstract][Full Text] [Related]
11. Combined seton placement, infliximab infusion, and maintenance immunosuppressives improve healing rate in fistulizing anorectal Crohn's disease: a single center experience. Topstad DR; Panaccione R; Heine JA; Johnson DR; MacLean AR; Buie WD Dis Colon Rectum; 2003 May; 46(5):577-83. PubMed ID: 12792431 [TBL] [Abstract][Full Text] [Related]
12. Basic fibroblast growth factor as a response parameter to infliximab in fistulizing Crohn's disease. Gao Q; Hogezand RA; Lamers CB; Verspaget HW Aliment Pharmacol Ther; 2004 Sep; 20(5):585-92. PubMed ID: 15339330 [TBL] [Abstract][Full Text] [Related]
13. Infliximab for the treatment of fistulas in patients with Crohn's disease. Present DH; Rutgeerts P; Targan S; Hanauer SB; Mayer L; van Hogezand RA; Podolsky DK; Sands BE; Braakman T; DeWoody KL; Schaible TF; van Deventer SJ N Engl J Med; 1999 May; 340(18):1398-405. PubMed ID: 10228190 [TBL] [Abstract][Full Text] [Related]
14. Optimizing anti-TNF treatment in inflammatory bowel disease. Rutgeerts P; Van Assche G; Vermeire S Gastroenterology; 2004 May; 126(6):1593-610. PubMed ID: 15168370 [TBL] [Abstract][Full Text] [Related]
15. Polymorphisms in apoptosis genes predict response to infliximab therapy in luminal and fistulizing Crohn's disease. Hlavaty T; Pierik M; Henckaerts L; Ferrante M; Joossens S; van Schuerbeek N; Noman M; Rutgeerts P; Vermeire S Aliment Pharmacol Ther; 2005 Oct; 22(7):613-26. PubMed ID: 16181301 [TBL] [Abstract][Full Text] [Related]
16. Clinical outcome of Crohn's disease treated with infliximab. Arslan S; Kav T; Besisik F; Kaymakoglu S; Pinarbasi B; Tözün N; Hamzaoglu HO; Duman D; Ulker A; Parlak E; Palabiyikoglu M; Dökmeci A Hepatogastroenterology; 2003; 50(52):952-6. PubMed ID: 12845957 [TBL] [Abstract][Full Text] [Related]
17. Remicade does not abolish the need for surgery in fistulizing Crohn's disease. Poritz LS; Rowe WA; Koltun WA Dis Colon Rectum; 2002 Jun; 45(6):771-5. PubMed ID: 12072629 [TBL] [Abstract][Full Text] [Related]
18. Infliximab in fistulizing Crohn's disease. Osterman MT; Lichtenstein GR Gastroenterol Clin North Am; 2006 Dec; 35(4):795-820. PubMed ID: 17129814 [TBL] [Abstract][Full Text] [Related]
19. Infliximab: an updated review of its use in Crohn's disease and rheumatoid arthritis. Keating GM; Perry CM BioDrugs; 2002; 16(2):111-48. PubMed ID: 11985485 [TBL] [Abstract][Full Text] [Related]
20. Scheduled maintenance treatment with infliximab is superior to episodic treatment for the healing of mucosal ulceration associated with Crohn's disease. Rutgeerts P; Diamond RH; Bala M; Olson A; Lichtenstein GR; Bao W; Patel K; Wolf DC; Safdi M; Colombel JF; Lashner B; Hanauer SB Gastrointest Endosc; 2006 Mar; 63(3):433-42; quiz 464. PubMed ID: 16500392 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]